Drug intelligence / Profile preview

PMR

Development stage: Preclinical
Lead developer: Sparrow Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

PMR is a test formulation of extended-release cilostazol, designed for once-daily administration. It is being evaluated in bioequivalence studies against the immediate-release formulation of cilostazol, which is typically administered twice-daily. Cilostazol is a phosphodiesterase 3 (PDE3) inhibitor, primarily used for the treatment of intermittent claudication.

Other names: extended-release tablet of cilostazol

Targets

PDE3

Beyond the preview

Go deeper on PMR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMR.

Explore the full profile